Publication
Title
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib : expanded access programme data from Belgium (the TRUST study)
Author
Abstract
Erlotinib has been shown to prolong progression-free (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). We report here on effectiveness data on the subsample of 261 patients from 40 centres in Belgium involved in the TRUST study. Median age was 63 years. Most (69.0%) were male and current/former smokers (84.7%); with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (74.3%), stage IV disease (75.1%) and adenocarcinoma by histology (54.0%). Erlotinib was administered mainly as second- (47.1%) or third-line treatment (48.3%). Response rate was 6.5%; disease control rate 58.3%. Median PFS was 2.2 months. Better PS (P=0.0384), stage IIIB disease (P=0.0018) and presence of rash (P<0.0001) were associated with longer PFS. OS rates at 1, 2 and 3 years were 26.4%, 10.9% and 6.4% respectively. Median OS was 5.9 months. Female gender (P=0.007), better PS (P<0.0001), stage IIIB disease (P=0.0355) and presence of rash (P<0.0001) were associated with longer OS. The findings confirm the therapeutic benefit of erlotinib in a broad range of patients in a sample from a country with a historically high lung cancer morbidity and mortality burden. Several determinants of PFS and OS are identified.
Language
English
Source (journal)
European journal of cancer care. - Oxford
Publication
Oxford : 2014
ISSN
0961-5423
Volume/pages
23:3(2014), p. 370-379
ISI
000334923100011
Full text (Publishers DOI)
Full text (publishers version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
External links
Web of Science
Record
Identification
Creation 18.11.2014
Last edited 24.05.2017